Takk for deling, AOL. Liker denne godt.
TG01 is currently being tested in lung cancer, pancreatic cancer and multiple myeloma, both in early and late settings and in different immunotherapy combinations. As this program reads out, Circio plans to select the most promising patient population and treatment combination to move into registrational development.
TG01 additionally plays a major advantage to Circio in having a more advanced clinical program with the potential to generate future revenues to invest into the circRNA platform development, which is the main priority for us due to its unique features and broad potential.